Arthur He CFA
Stock Analyst at H.C. Wainwright
(4.89)
# 279
Out of 4,491 analysts
133
Total ratings
60.5%
Success rate
41.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSX: MSCL Satellos Bioscience Inc. | Reiterated: Buy | $15.58 → $25.49 | $12.62 | +102.01% | 13 | Jul 9, 2026 | |
| PRME Prime Medicine | Reiterated: Buy | $8 | $4.62 | +73.16% | 17 | Jul 9, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | $110 → $125 | $42.43 | +194.60% | 12 | Jul 8, 2026 | |
| NKTR Nektar Therapeutics | Reiterated: Buy | $185 | $71.90 | +157.30% | 18 | Jul 1, 2026 | |
| SLDB Solid Biosciences | Reiterated: Buy | $25 | $11.00 | +127.27% | 20 | Jul 1, 2026 | |
| JBIO Jade Biosciences | Rated: Buy | $45 → $55 | $22.53 | +144.12% | 5 | Jun 1, 2026 | |
| ADAG Adagene | Reiterated: Buy | $7 | $3.83 | +82.77% | 18 | Apr 7, 2026 | |
| AUPH Aurinia Pharmaceuticals | Reiterated: Buy | $17 | $16.23 | +4.74% | 3 | Feb 27, 2026 | |
| BCAB BioAtla | Reiterated: Hold | n/a | $3.59 | - | 15 | Aug 11, 2025 | |
| ADAPY Adaptimmune Therapeutics plc | Downgraded: Hold | n/a | $0.036 | - | 8 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $22.70 | n/a | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27.00 → $35.00 | $26.88 | n/a | 3 | Apr 3, 2023 |
Satellos Bioscience Inc.
Jul 9, 2026
Reiterated: Buy
Price Target: $15.58 → $25.49
Current: $12.62
Upside: +102.01%
Prime Medicine
Jul 9, 2026
Reiterated: Buy
Price Target: $8
Current: $4.62
Upside: +73.16%
Vera Therapeutics
Jul 8, 2026
Reiterated: Buy
Price Target: $110 → $125
Current: $42.43
Upside: +194.60%
Nektar Therapeutics
Jul 1, 2026
Reiterated: Buy
Price Target: $185
Current: $71.90
Upside: +157.30%
Solid Biosciences
Jul 1, 2026
Reiterated: Buy
Price Target: $25
Current: $11.00
Upside: +127.27%
Jade Biosciences
Jun 1, 2026
Rated: Buy
Price Target: $45 → $55
Current: $22.53
Upside: +144.12%
Adagene
Apr 7, 2026
Reiterated: Buy
Price Target: $7
Current: $3.83
Upside: +82.77%
Aurinia Pharmaceuticals
Feb 27, 2026
Reiterated: Buy
Price Target: $17
Current: $16.23
Upside: +4.74%
BioAtla
Aug 11, 2025
Reiterated: Hold
Price Target: n/a
Current: $3.59
Upside: -
Adaptimmune Therapeutics plc
Jul 29, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.036
Upside: -
Jun 21, 2024
Maintained: Buy
Price Target: n/a
Current: $22.70
Upside: n/a
Apr 3, 2023
Maintained: Buy
Price Target: $27.00 → $35.00
Current: $26.88
Upside: n/a